Morningstar Gives Illumina a BB+ Credit Rating

Morningstar said that the rating reflects its negative view of the genetic analysis instrument business and potential competitive pressure for Illumina.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.